Press Release January 28, 2022Blueprint Medicines' AYVAKYT® (avapritinib) Receives Positive CHMP Opinion for the Treatment of Adults with Advanced Systemic Mastocytosis 0 0 Share
Press Release January 20, 2022Blueprint Medicines Elevates Two Talented Leaders to its Executive Team 0 0 Share
Press Release January 10, 2022Blueprint Medicines Provides 2022 Portfolio Goals Targeting Expanded Precision Therapy Leadership 0 0 Share
Press Release January 7, 2022Blueprint Medicines Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) 0 0 Share
Company Ticker News January 5, 2022Blueprint Medicines Announces CEO and Leadership Transition Plan 0 0 Share
Company Ticker News January 1, 2022Blueprint Medicines (BPMC) Up 24.8% in Past 6 Months: Here's Why 0 0 Share
Company Ticker News December 30, 2021Blueprint Medicines Completes Acquisition of Lengo Therapeutics 0 0 Share
Company Ticker News December 1, 2021Blueprint Medicines (BPMC) Set to Acquire Lengo Therapeutics 0 0 Share
Company Ticker News November 29, 2021Blueprint Medicines to Expand Precision Therapy Leadership in Lung Cancer with Acquisition of Lengo Therapeutics 0 0 Share
Company Ticker News November 29, 2021Blueprint Medicines Expands Precision Therapy With Lengo Therapeutics Acquisition 0 0 Share
